147 related articles for article (PubMed ID: 3024666)
1. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant.
Christomanou H; Aignesberger A; Linke RP
Biol Chem Hoppe Seyler; 1986 Sep; 367(9):879-90. PubMed ID: 3024666
[TBL] [Abstract][Full Text] [Related]
2. Isolation of two forms of an activator protein for the enzymic sphingomyelin degradation from human Gaucher spleen.
Christomanou H; Kleinschmidt T
Biol Chem Hoppe Seyler; 1985 Mar; 366(3):245-56. PubMed ID: 4005041
[TBL] [Abstract][Full Text] [Related]
3. Niemann-Pick disease, Type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation.
Christomanou H
Hoppe Seylers Z Physiol Chem; 1980 Oct; 361(10):1489-502. PubMed ID: 6256275
[TBL] [Abstract][Full Text] [Related]
4. Saposin D: a sphingomyelinase activator.
Morimoto S; Martin BM; Kishimoto Y; O'Brien JS
Biochem Biophys Res Commun; 1988 Oct; 156(1):403-10. PubMed ID: 2845979
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the multiple forms of Gaucher spleen sphingolipid activator protein 2.
Paton BC; Poulos A
Biochem J; 1988 Aug; 254(1):77-84. PubMed ID: 3178760
[TBL] [Abstract][Full Text] [Related]
6. Studies on a sphingolipid activator protein (SAP-2) in fibroblasts from patients with lysosomal storage diseases, including Niemann-Pick disease Type C.
Fujibayashi S; Wenger DA
Clin Chim Acta; 1985 Mar; 146(2-3):147-56. PubMed ID: 3921288
[TBL] [Abstract][Full Text] [Related]
7. Studies on the activation of sphingomyelinase activity in Niemann-Pick type A, B, and C fibroblasts: enzymological differentiation of types A and B.
Poulos A; Ranieri E; Shankaran P; Callahan JW
Pediatr Res; 1984 Nov; 18(11):1088-93. PubMed ID: 6096798
[TBL] [Abstract][Full Text] [Related]
8. Complete amino-acid sequence and carbohydrate content of the naturally occurring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant.
Kleinschmidt T; Christomanou H; Braunitzer G
Biol Chem Hoppe Seyler; 1987 Dec; 368(12):1571-8. PubMed ID: 3442600
[TBL] [Abstract][Full Text] [Related]
9. Complete amino-acid sequence of the naturally occurring A2 activator protein for enzymic sphingomyelin degradation: identity to the sulfatide activator protein (SAP-1).
Kleinschmidt T; Christomanou H; Braunitzer G
Biol Chem Hoppe Seyler; 1988 Dec; 369(12):1361-5. PubMed ID: 3242555
[TBL] [Abstract][Full Text] [Related]
10. N-terminal amino-acid sequence of a sphingolipid activator protein missing in a new human Gaucher disease variant.
Christomanou H; Kleinschmidt T; Braunitzer G
Biol Chem Hoppe Seyler; 1987 Sep; 368(9):1193-6. PubMed ID: 3675870
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evidence for a processing error in the biosynthesis of Gaucher activator in mucolipidosis disease types II and III.
Ranieri E; Paton B; Poulos A
Biochem J; 1986 Feb; 233(3):763-72. PubMed ID: 3518703
[TBL] [Abstract][Full Text] [Related]
12. Studies on the activation of the enzymatic hydrolysis of sphingomyelin liposomes.
Poulos A; Ranieri E; Shankaran P; Callahan JW
Biochim Biophys Acta; 1984 Apr; 793(2):141-8. PubMed ID: 6712963
[TBL] [Abstract][Full Text] [Related]
13. Purification and properties of a heat-stable glucocerebrosidase activating factor from control and Gaucher spleen.
Peters SP; Coyle P; Coffee CJ; Glew RH
J Biol Chem; 1977 Jan; 252(2):563-73. PubMed ID: 13071
[TBL] [Abstract][Full Text] [Related]
14. Enzyme activities and phospholipid storage patterns in brain and spleen samples from Niemann-Pick disease variants: a comparison of neuropathic and non-neuropathic forms.
Besley GT; Elleder M
J Inherit Metab Dis; 1986; 9(1):59-71. PubMed ID: 3014212
[TBL] [Abstract][Full Text] [Related]
15. Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder.
Christomanou H; Chabás A; Pámpols T; Guardiola A
Klin Wochenschr; 1989 Oct; 67(19):999-1003. PubMed ID: 2615292
[TBL] [Abstract][Full Text] [Related]
16. Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.
Aerts JM; Donker-Koopman WE; Brul S; Van Weely S; Sa Miranda MC; Barranger JA; Tager JM; Schram AW
Biochem J; 1990 Jul; 269(1):93-100. PubMed ID: 2198026
[TBL] [Abstract][Full Text] [Related]
17. The cohydrolases in human spleen that stimulate glucosyl ceramide beta-glucosidase.
Iyer SS; Berent SL; Radin NS
Biochim Biophys Acta; 1983 Oct; 748(1):1-7. PubMed ID: 6615847
[TBL] [Abstract][Full Text] [Related]
18. In situ radiation-inactivation size of fibroblast membrane-bound acid beta-glucosidase in Gaucher type 1, type 2 and type 3 disease.
Choy FY; Woo M; Potier M
Biochim Biophys Acta; 1986 Mar; 870(1):76-81. PubMed ID: 3947649
[TBL] [Abstract][Full Text] [Related]
19. Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease.
Ginns EI; Brady RO; Pirruccello S; Moore C; Sorrell S; Furbish FS; Murray GJ; Tager J; Barranger JA
Proc Natl Acad Sci U S A; 1982 Sep; 79(18):5607-10. PubMed ID: 6957882
[TBL] [Abstract][Full Text] [Related]
20. Immunological evidence for deficiency in an activator protein for sulfatide sulfatase in a variant form of metachromatic leukodystrophy.
Inui K; Emmett M; Wenger DA
Proc Natl Acad Sci U S A; 1983 May; 80(10):3074-7. PubMed ID: 6134282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
